Healios K.K. to Present at the Chardan Genetic Medicines Conference
Healios K.K. is excited to announce that Richard Kincaid, the Chief Financial Officer, will be taking the stage to present at the Chardan 9th Annual Genetic Medicines Conference. This high-profile event provides an excellent platform for Healios to share its groundbreaking innovations in the field of regenerative medicine.
Event Details
Healios is scheduled to present at the following time:
- Date: Tuesday, October 21
- Time: 2:00 PM Eastern Time (US)
- Webcast: The presentation will be accessible live, as well as in an archived format for future viewing. The replay will be available for a duration of 60 days following the conference.
Scheduled meetings with Healios representatives can be arranged through your Chardan contact.
Get to Know Healios K.K.
As one of Japan's leading clinical-stage biotechnology companies, HEALIOS K.K. is at the forefront of leveraging stem cell technology for treating various severe conditions. Their mission revolves around creating innovative therapies tailored for patients who currently face a lack of effective treatment options.
Innovative Therapies and Technologies
Among Healios's impressive pipeline is MultiStem (HLCM051), a proprietary cell product derived from healthy adult donor bone marrow. This multipotent adult progenitor cell product exhibits significant anti-inflammatory and immunomodulatory properties, proving effective across numerous disease states. Healios has successfully conducted extensive clinical trials, showcasing not only the safety but also the potential efficacy of MultiStem in a range of therapeutic applications including acute respiratory distress syndrome (ARDS), trauma recovery, and ischemic stroke.
Exploring iPSC Technology
In addition to its work with somatic stem cells, Healios is pioneering advancements in induced pluripotent stem cell (iPSC) regenerative medicine. They have developed HLCN061, an innovative NK cell treatment for solid tumors, enhanced through gene-editing technologies. This next-generation therapy has demonstrated robust anti-tumor activity in preclinical models and is set for initial human testing in collaboration with Akatsuki Therapeutics.
Company Overview
Founded in 2011, Healios K.K. has established itself as a key player in the biotechnology sector, having been publicly listed on the Tokyo Stock Exchange since 2015 under the ticker symbol JPX: 4593. Continually evolving, Healios has also initiated the development of a proprietary gene-edited “universal donor” iPSC line, aimed at addressing critical needs in immuno-oncology, liver disease, and other challenging health conditions.
Leadership and Contact Information
Healios is led by Hardy TS Kagimoto, the Chairman and CEO, alongside Richard Kincaid, who serves as the Executive Officer and Chief Financial Officer. Investors looking to connect with the company can reach out through the designated representatives listed below:
- U.S. Investor Relations: Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com - Richard Kincaid: Executive Officer and CFO
E-mail: ir@healios.jp
Frequently Asked Questions
What is the main focus of Healios K.K.?
Healios K.K. primarily focuses on regenerative medicine, utilizing stem cell technology to develop therapies for serious health conditions.
Who is presenting at the conference?
Richard Kincaid, the Chief Financial Officer of Healios K.K., will be presenting at the Chardan Genetic Medicines Conference.
Where can the conference webcast be accessed?
The live and recorded webcasts can be accessed via Chardan’s official website.
What groundbreaking products is Healios developing?
Healios is developing MultiStem for various conditions and HLCN061 for solid tumors with gene-edited NK cells.
How can investors contact Healios K.K.?
Investors can reach out via the designated contact for U.S. Investor Relations or directly to Richard Kincaid for inquiries.
